416 related articles for article (PubMed ID: 18513264)
1. Combining proof-of-concept with dose-finding: utilization of adaptive designs in migraine clinical trials.
Sagkriotis A; Scholpp J
Cephalalgia; 2008 Aug; 28(8):805-12. PubMed ID: 18513264
[TBL] [Abstract][Full Text] [Related]
2. A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials.
Hall DB; Meier U; Diener HC
Contemp Clin Trials; 2005 Jun; 26(3):349-64. PubMed ID: 15911469
[TBL] [Abstract][Full Text] [Related]
3. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
[TBL] [Abstract][Full Text] [Related]
4. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
5. Innovative approaches for designing and analyzing adaptive dose-ranging trials.
Bornkamp B; Bretz F; Dmitrienko A; Enas G; Gaydos B; Hsu CH; König F; Krams M; Liu Q; Neuenschwander B; Parke T; Pinheiro J; Roy A; Sax R; Shen F
J Biopharm Stat; 2007; 17(6):965-95. PubMed ID: 18027208
[TBL] [Abstract][Full Text] [Related]
6. Flexible two-stage design with sample size reassessment for survival trials.
Desseaux K; Porcher R
Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
[TBL] [Abstract][Full Text] [Related]
7. Adaptive methods: telling "the rest of the story".
Emerson SS; Fleming TR
J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
9. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
Polley MY; Cheung YK
Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
[TBL] [Abstract][Full Text] [Related]
10. Adaptive designs for confirmatory clinical trials.
Bretz F; Koenig F; Brannath W; Glimm E; Posch M
Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
[TBL] [Abstract][Full Text] [Related]
11. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
Morgan CC; Stephen Coad D
Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
[TBL] [Abstract][Full Text] [Related]
12. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
13. Estimation in flexible two stage designs.
Brannath W; König F; Bauer P
Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
[TBL] [Abstract][Full Text] [Related]
14. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
15. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
16. Optimal designs for estimating the interesting part of a dose-effect curve.
Miller F; Guilbaud O; Dette H
J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
[TBL] [Abstract][Full Text] [Related]
17. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
[TBL] [Abstract][Full Text] [Related]
18. ISCTM: Implementing phase 2 dose finding adaptive clinical trials.
Parke T
Eur Neuropsychopharmacol; 2011 Feb; 21(2):167-74. PubMed ID: 20947316
[TBL] [Abstract][Full Text] [Related]
19. Adaptive two-stage designs in phase II clinical trials.
Banerjee A; Tsiatis AA
Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
[TBL] [Abstract][Full Text] [Related]
20. Statistical analysis for two-stage seamless design with different study endpoints.
Chow SC; Lu Q; Tse SK
J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
